“Smart” drug targets site-specific inflammation

Ben-Gurion University‘s Peleg Rider has developed a drug that targets inflammation in a site-specific manner.  This could improve the body’s  ability to fight infection and reduce side effects.

When injected, it is a non-active drug.  A localized site with excessive inflammation will activate it.  Other anti-inflammatory agents inhibit inflammatory processes throughout the body, including sites of necessary normal inflammatory homeostasis.

When a non-specific agent is used, a patient who suffers from local inflammation might  be exposed to infections at distant sites, such as the lungs. This risk is increased in immunosuppressed, older, and chemotherapy patients.


Posted

in

by

Tags: